Eisai To File Dacogen sNDA for Out-Patient MDS, Despite Less Than Stellar Survival Data
This article was originally published in PharmAsia News
Executive Summary
TOKYO - As part of its strategy to reinforce its oncology and innovative pharmaceutical products, Eisai July 1 said its ongoing clinical trial comparing Dacogen with best supportive care in elderly patients with myelodysplastic syndromes, a bone marrow disease, had registered results that would enable the company to submit for applying the treatment on an out-patient basis, instead of in-hospital treatment
You may also be interested in...
Japan’s Eisai Looks To MGI Pharma Acquisition For Growth
Japan's Eisai is looking to expanded sales of MGI Pharma in its home country of the United States for the acquiring company's own improvement. MGI's CEO Lonnie Moulder expects Eisai's acquisition to be symbiotic, with Eisai's sales staff combining with MGI's to put 900 representatives on the ground in the United States. Eisai looks to the MGI tie to counteract a reduction it faces in its own drug pipeline as patents on key products expire. Other Japanese drug makers have chosen to merge with each other. (Click here for more - a subscription may be required
China And India Next Targets For Eisai’s Global Plan
Eisai will look to China and India for investment opportunities after establishing a strong oncology presence in the U.S
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).